HollyCatheryn
New member
Bear with me, this is a little long, but it is definitely worth knowing and checking out. The numbers notated (ex. *213*) correspond to footnotes which I will include here so that you can look up any and all of the information quoted. This is the entire section on RSV from <U><STRONG>Vaccines</STRONG></U> by Neil Z. Miller. It contains "information on all recommended childhoodshots plus Anthrax, Smallpox, and Flu."Backgroud information on RSV"Respiratory syncytial virus (RSV) is the most common cause of bronchiolitis and pneumonia among infants and children under one year of age.*515* It also causes severe respiratory illness in the elderly.*516* RSV is very contagious.Symptoms are initially similar to the common cold, then worsen as the infected person develops fever, wheezing, and difficulty breathing. Most healthy children recover in one to two weeks.*517, 518* However, during their first RSV infection, about one percent of infants will require hospitalization.*519* Some people die from complications of the disease.*520*Treatment of severe RSV infection is mainly supportive: oxygen therapy, hydration, and nutrition.*521* A vaccine does not yet exist. Researchers have been hampered by the mutable nature of the organism, and "early attempts [at developing a vaccine] actually made the disease worse on subsequent infection."*522* However, two "preventative agents" were licensed by the FDA. In 1996, Respigam, an immune globulin treatment made from human plasma, became available.*523* In 1998, Synagis, a "monoclonal antibody" produced in human and mouse genes, entered the market.*524, 525*<STRONG><U>Findings:</U></STRONG> In 1956, respiratory syncytial virus (RSV) was discovered in chimpanzees.*526* According to Dr. Viera Scheibner, who studied more than 30,000 pages of medical papers dealing with vaccination, RSV viruses "formed prominent contaminants in polio vaccines, and were soon detected in children."*527* They caused serious cold-like symptoms in small infants and babies who received the polio vaccine.*528* In 1961, the <EM>Journal of the Amercian Medical Association</EM> published two studies confirming a causal relationship between RSV and "relatively severe lower respiratory tract illness."*529, 530* The virus was found in 57 percent of infants with bronchiolitis or pneumonia, and in 12 percent of babies with a milder febrile respiratory disease. Infected babies remained ill for three to five months.*531* RSV was also found to be contagious, and soon spread to adults where it has been linked to the common cold.*532* Today, children who are most at risk of serious complications from RSV include infants born prematurely or with chronic lung disease, immune system problems, neuromuscular disorders, congenital heart disease, and other pre-existing conditions.*533*Synagis is given as a series of five monthyl injections at the start of and during the RSV season (usually November to April). It is very expensive; each injection may cost $900 or more.*534* One mother reported being charged more than $7,000 for a single dose and $2600 for each subsequent dose. Her insurance did not pay.*535* Synagis is indicated for the prevention of serious <EM>lower</EM> respiratory tract infections caused by RSV. Studies show that it will not alter the incidence and mean duration of hospitalization for non-RSV respiratory illness nor will it prevent <EM>upper</EM> respiratory tract infections.*536, 537* In fact, clinical studies indicate that children receiving Synagis are <EM>more likely</EM> to experience upper respiratory tract infections than children who do not receive it.*538* Furthermore, some children will develop RSV despite having received Synagis. The data suggests that their illnesses will be no less severe than children who develop RSV without Synagis.*539*In a controlled clinical study, Synagis was found to increase the likelihood of developing otitis media (an ear infection), rhinitis, pharyngitis, rash, pain, and hernia.*540* Other adverse events reported in children receiving this "preventative" biotech commodity include: fever, cough, wheeze, bronchiolitis, pneumonia, bronchitis, asthma, croup, dyspnea, sinusitis, apnea, diarrhea, vomiting, liver function abnormality, viral infection, fungal dermatitis, eczema, seborrhea, conjunctivitis, anemia, flu syndrome, and failure to thrive.*541*"*515* CDC. "Respiratory syncytial virus." National Center for Infectious Disease, 1999. <A href="http://www.cdc.gov/ncidod/dvrd/nrevss/rsvfeat.htm">w<U>ww.cdc.gov/ncidod/dvrd/nrevss/rsvfeat.htm</A></U>*516* Public Health Laboratory Service, United Kingdom. "Seasonal diseases: respiratory syncytial virus (RSV) infections." <A href="http://www.phls.co.uk/seasonal/rsv/RSV13.htm">www.phls.co.uk/seasonal/rsv/RSV13.htm</A> (March 16, 2000.)*517* Baltimore, J.G. "RSV--a serious subject." <EM>The Triplet Connection</EM>, 2000. <A href="http://www.tripletconnection.com/rsv_new.html">www.tripletconnection.com/rsv_new.html</A>*518* See Note 515.*519* Ibid.*520* See Note 517.*521* Travel and Health. "Questions and answers on Synagis." <A href="http://www.travelandhealth.com/synagis.htm">www.travelandhealth.com/synagis.htm</A>*522* Applied Genetic News. "Eat your vaccine, dear." <EM>Business Communications Company</EM> (August 2000). <A href="http://www.findarticles.com/cf_dls/m0DED/1_21/65016226/pl/article.jhtml">www.findarticles.com/cf_dls/m0DED/1_21/65016226/pl/article.jhtml</A>*523* See Note 517.*524* FDA. "FDA licenses biotech product to prevent serious RSV disease." <EM>U.S. Department of Health and Human Services</EM> (June 19, 1998). <A href="http://www.fda.gov/bbs/topics/answers/ans00878.html">www.fda.gov/bbs/topics/answers/ans00878.html</A>*525* Package Inserts. "Synagis (Palivizumab) for intramuscular administration." <EM>Medimmune, Inc</EM>., 1999. <A href="http://www.medimmune.com/products/htmlpis/synagispi.html">www.medimmune.com/products/htmlpis/synagispi.html</A>*526* Morris, J.A., et al. "Recovery of cytopathogenic agent from chimpanzees with coryza (22538)." <EM>Proc Soc Exp Biol Med</EM> 1956; 92:544-49*527* See Note 210, p.153. *210* Scheibner, Viera. <EM>Vaccination: 100 Years of Orthodox Research Shows that Vaccines Represent a Medical Assault on the Immune System.</EM> (Blackheath, NSW, Australia: Scheibner Publications, 1993)*528* Ibid.*529* Parrot, R.H., et al. "Il. Serological studies over a 34-month period in children with bronchiolitis, pneumonia and minor respiratory diseases." <EM>Journal of the American Medical Association</EM> 1961; 176(8):653-57.*530* Chanock, R.M., et al. "Respiratory syncytial virus." <EM>Journal of the American Medical Association</EM> 1961; 176(8):647-53.*531* Ibid.*532* Hamparian, V., et al. "Recovery of new viruses (coryza) from cases of common cold in human adults." <EM>Proc Soc Exp Med Biol</EM> 1961; 108:444-453.*533* Keep Kids Healthy. "Preventing RSV." <A href="http://www.keepkidshealthy.com/welcome/infectionsguide/preventing_rsv.html">www.keepkidshealthy.com/welcome/infectionsguide/preventing_rsv.html</A> (2002.) *534* Ibid.*535* "More on cost of synagis..." (Posted March 26, 1999 on an internet forum.) <A href="http://www.home.vicnet.net.au/~garyh/preemie_forum/old-messages/4799.html">www.home.vicnet.net.au/~garyh/preemie_forum/old-messages/4799.html</A>*536* The Impact RSV Study Group. "Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants." <EM>Pediatrics</EM> 1998; 102:531-537.*537* See Note 525.*538* See Notes 525 and 536.*539* Ibid.*540* Ibid.*541* Ibid.Happy Researching <img src="i/expressions/face-icon-small-smile.gif" border="0">